<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum></forum>
<forum_title></forum_title>
<discussion_title>Valeant&apos;s new CEO a good choice for a dim future</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.cnbc.com/2016/04/25/valeants-new-ceo-a-good-choice-for-a-dim-future.html</topic_url>
<topic_text>
Valeant&apos;s new CEO a good choice for a dim future Robert Cyran CNBC Joseph Papa 
Valeant Pharmaceuticals &apos; new chief executive is a good choice for a dim future. Joseph Papa&apos;s skill running a tight ship at Perrigo is sorely lacking at his new company. Valeant needs to keep staff, sell assets and pay down the company&apos;s $30 billion of debt, all while coping with drug pricing pressures that have also hit the rest of the industry. Related Securities 
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.cnbc.com/2016/04/25/valeants-new-ceo-a-good-choice-for-a-dim-future.html</post_url>
<post_date>20160425</post_date>
<post_time></post_time>
<username>Robert Cyran</username>
<post>
Valeant&apos;s new CEO a good choice for a dim future Robert Cyran CNBC Joseph Papa 
Valeant Pharmaceuticals &apos; new chief executive is a good choice for a dim future. Joseph Papa&apos;s skill running a tight ship at Perrigo is sorely lacking at his new company. Valeant needs to keep staff, sell assets and pay down the company&apos;s $30 billion of debt, all while coping with drug pricing pressures that have also hit the rest of the industry. Related Securities 
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2016/04/25/103576698-JosephPapa02r.1910x1000.jpg</main_image>
</document>
